Background: First and second line standard treatment in patients with metastatic colorectal cancer (mCRC) is with chemotherapy +/- some monoclonal antibody according to the RAS biomarker report. About 30-40% of them will require a third line of therapy, where regorafenib has been approved due to ove...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Permanyer
2021-10-01
|
| Series: | Gaceta Mexicana de Oncología |
| Subjects: | |
| Online Access: | https://www.gamo-smeo.com/frame_esp.php?id=269 |